Patient-reported outcomes during repetitive pressurized intraperitoneal aerosol chemotherapy (oxaliplatin) for unresectable colorectal peritoneal metastases: a multicenter, single-arm, phase 2 trial

Robin Lurvink,Koen Rovers,Emma Wassenaar,Checca Bakkers,Pim Burger,Geert-Jan Creemers,Maartje Los,Floortje Mols,René Wiezer,Simon Nienhuijs,Djamila Boerma,Ignace De Hingh

doi:10.1016/j.ejso.2021.12.311

Patient-reported outcomes during repetitive pressurized intraperitoneal aerosol chemotherapy (oxaliplatin) for unresectable colorectal peritoneal metastases: a multicenter, single-arm, phase 2 trial

Robin Lurvink, Koen Rovers + Show 10 more

https://doi.org/10.1016/j.ejso.2021.12.311

Copy DOI

Journal: European Journal of Surgical Oncology

Publication Date: Feb 1, 2022

Affiliation: Catharina Ziekenhuis, Radboud University Nijmegen, St. Antonius Ziekenhuis, Tilburg University, Netherlands Comprehensive Cancer Organisation, Maastricht University

#Pressurized Intraperitoneal Aerosol Chemotherapy #Concomitant Systemic Therapy + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Background: CRC-PIPAC is the first trial assessing repetitive oxaliplatin-based pressurized intraperitoneal aerosol chemotherapy (PIPAC-OX) as a palliative monotherapy (i.e. without concomitant systemic therapy) for unresectable colorectal peritoneal metastases (CPM). The present study explored patient-reported outcomes (PROs) during trial treatment.

Full Text